[Raltegravir in a special case: patient with HIV and Burkitt's lymphoma].

History And Clinical Findings: A 38-year-old HIV positive man suffered from right upper abdominal pain and oesophageal reflux syndromes. He was in a good general state of health and nutrition with no concomitant symptoms.

Investigations: A small bowel tumor and slight soor esophagitis had been diagnosed by esophago-gastroduodenoscopy.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

Objectives: Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with efavirenz pharmacokinetics. Since the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) correlate with CYP2B6 in liver, and a CAR polymorphism (rs2307424) and smoking correlate with efavirenz plasma concentrations, we investigated their association with early (<3 months) discontinuation of efavirenz therapy.

Methods: Three hundred and seventy-three patients initiating therapy with an efavirenz-based regimen were included (278 white patients and 95 black patients; 293 male).

Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV.

A central, yet unresolved issue in the pathogenesis of HIV disease is the mechanism of antibody perturbation. In this study, HIV-specific memory B-cells were quantified in groups of infected subjects and compared with memory responses to other antigens and antibody titers. HIV-specific memory B-cell responses were vigorous in individuals with CD4(+) T-cell counts >350/microl and weak or undetectable in subjects with CD4(+) T-cell numbers <200/microl.

Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study.

Background: Data on the clinical course of infection in patients with transmitted drug-resistant HIV before and after initiation of treatment are scarce.

Patients And Methods: Genotypic resistance was analysed in 504 therapy-naïve individuals with a known date of infection. Resistance was predicted using the Stanford algorithm.

Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

Background: Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic.

Methods: Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of hepatitis C infection with pegylated interferon (peg-IFN) therapy.

Results: Early treatment resulted in sustained virological response in 61% of patients.